Your Voice Box
Tapping into the reader experience, our new comprehensive survey uncovers valuable input for navigating the changing tides facing pharma decision-makers.
While we're always close to the pulse of the pharma industry in our day-to-day coverage and content offerings, it had been a bit since Pharmaceutical Executive conducted a formal, deep-dive survey of our readers—and top decision-makers in the field—to gauge their feelings on the landscape in one broad stroke.
Nearing the most recent calendar turn, the editorial team felt there was probably no better and more opportune time to launch such an outreach. Industry trends were accelerating fast and furious and, though uncertain what levels they might reach as we sit here today, further transition and transformation were clearly on the horizon.
It was the perfect storm to collect valuable input on the issues and strategies that matter most to Pharm Exec’s audience and customers, and help shape our editorial coverage accordingly.
To that end, we invite you, in our May digital issue, to peruse the key highlights and takeaways from Pharm Exec’s 2025 State of the Industry Survey. Starting on page 26, the special presentation parses out select data, in chart form, across such trends and challenges involving market access, commercial strategy, drug pricing and policy, artificial intelligence, and sustainability, among other areas. Additional results can be found in our online slideshow version.
The insights are abundant and we hope informative and actionable in your day-to-day. More specific tariff-related impacts and the like were not quite visible yet, which you can argue remains the case today, amid the still uncertain picture around planned US pharma tariffs.
We would like to extend a big thanks to all our esteemed readers who participated in the survey or shared with others. We are forever grateful for your longtime support. After all, “data storytelling” is the future of our business, and, for us, your feedback is core to that mission.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
